Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma

Piccoli, Michelly F.; Figueira, Marcia; Andreoni, Cássio; Marumo, Júlio Takehiro; Schor, Nestor; Bellini, Maria Helena

doi:10.1590/s1677-55382007000500003

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found only one Chinese article in the WanFang database. As a result, 12 case-control articles were included in our meta-analysis: (Hirata et al, 2004;Zhong et al, 2005;Kader et al, 2006;Albayrak et al, 2007;Piccoli et al, 2007;Tasci et al, 2008;Tsuchiya et al, 2009;Srivastava et al, 2010aSrivastava et al, , 2010bWieczorek et al, 2013Wieczorek et al, , 2014Srivastava et al, 2013a) (Fig. 1).…”

Section: Eligible Studiesmentioning

confidence: 99%

“…studies, several polymorphisms in the promoters of a number of MMP genes have been well characterized. These polymorphisms may affect the production or gene expression of these MMPs in an allele-specific manner (Piccoli et al, 2007;Tsuchiya et al, 2009;Wieczorek et al, 2013;Yaykas xli et al, 2014). Furthermore, there is an increasing evidence indicating that these functional polymorphisms may contribute to interindividual differences in a wide spectrum of cancer susceptibility (Decock et al, 2008;Pereira et al, 2012;Wieczorek et al, 2012).…”

Section: Figmentioning

confidence: 99%

“…A quantitative synthesis to accumulate data from different studies is needed to provide better evidence on these associations. Here, in this report, we performed a meta-analysis of 12 publications to estimate the effect of eight polymorphisms: MMP1 -1607 1G/2G (Hirata et al, 2004;Kader et al, 2006;Albayrak et al, 2007;Piccoli et al, 2007;Tasci et al, 2008;Tsuchiya et al, 2009;Srivastava et al, 2010a;Wieczorek et al, 2013), MMP2 -1306 C/T (Zhong et al, 2005;Kader et al, 2006;Srivastava et al, 2013a;Wieczorek et al, 2013), MMP3 (45E/K) G/A (Kader et al, 2006;Srivastava et al, 2010b), MMP7 -181 A/G (Srivastava et al, 2010a;Wieczorek et al, 2014), MMP9 -1562 C/T (Zhong et al, 2005;Kader et al, 2006;Wieczorek et al, 2013), MMP9 (279R/Q) A/G (Kader et al, 2006;Tasci et al, 2008;Srivastava et al, 2010b), and MMP9 (574R/P) T/C (Kader et al, 2006;Srivastava et al, 2010b), MMP9 (668Q/R) A/G (Kader et al, 2006;Srivastava et al, 2010b) on urinary cancer risk.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MMP1, 2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis

Liu

Zuo

et al. 2015

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Background: The matrix metalloproteinases (MMPs) are a family of highly conserved, metal-dependent proteolytic enzymes that play an important role in tumor invasion and metastasis. Many studies have been carried out on the association between polymorphisms in the MMP1, MMP2, MMP3, MMP7, and MMP9 genes and urinary cancer risk. However, the data from these published studies are conflicting and have low statistical power. Methods: In this study, we performed a meta-analysis of 12 different publications from the PubMed and WanFang databases, published up to May 2015, to better assess the purported associations. Odds ratios (OR) and 95% confidence intervals (CI) were determined to reveal association strengths. Results: Some significant associations were found. For the MMP1 -1607 1G/2G polymorphism, a negative association was identified for the 2G allele in bladder cancer (2G2G+2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.36-0.93, p heterogeneity = 0.001) and renal cell carcinoma (2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.39-0.82, p heterogeneity = 0.567). For the MMP2 -1306 C/T polymorphism, there was a negative association with the T allele for bladder cancer in the Asian population (TT+TC vs. CC: OR = 0.41, 95% CI = 0.18-0.94, p heterogeneity = 0.195). For the MMP7 -181 A/G polymorphism, a decreased bladder cancer risk was found (G-allele vs. A-allele: OR = 0.81, 95% CI = 0.66-0.98, p heterogeneity = 0.325). Conclusion: In summary, our study showed evidence that genetic polymorphisms in MMP1 for all populations, but only in the Asian population for MMP2 and MMP7, may protect against bladder cancer risk. Future studies with larger sample sizes are warranted to further evaluate these associations in more detail.

show abstract

Section: Eligible Studiesmentioning

confidence: 99%

Section: Figmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MMP1, 2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis

Liu

Zuo

et al. 2015

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

show abstract

Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma

Wang

Huang

Yin

et al. 2011

European Journal of Cancer

View full text Add to dashboard Cite

Matrix Metallopeptidase 1 (MMP1) is one of the interstitial collagens in the extracellular matrix metalloproteinase family and involved in tumor behaviors. However, there is no report on the role of genetic variation in MMP1 in risk of cutaneous melanoma (CM). We investigated the association between genotypes and haplotypes of seven reported MMP1 promoter polymorphisms (-1607 G ins/del, -839G>A, -755T>G, -519A>G, -422A>T, -340A>G, and -320T>C, genotyped by the TaqMan assay) and CM risk in 872 patients and 873 cancer-free controls. These seven polymorphisms were not in linkage disequilibrium among each other (r 2 < 0.63). Compared to their common homozygous genotypes, the variant -519GG was associated with significantly decreased CM risk (adjusted odds ratio [OR] = 0.71, 95% confidence interval [CI] = 0.52-0.99), whereas variant -422TT and -320CC were associated with significantly increased CM risk (OR = 1.50, 95% CI = 1.11-2.03 and OR = 1.72, 95% CI = 1.05-2.81, respectively) after adjustment for age, sex, family history, and sun-exposure related risk factors. The number of risk alleles of these three polymorphisms was associated with CM risk in a dose-response manner (P trend = 0.0002). In the stratification analysis, we found that the associations of these polymorphisms with CM risk were modified by some of the risk factors. Furthermore, the haplotypes Gdel-A-G-A-T-G-T and G-G-G-A-T-A-T were associated with significantly increased CM risk (ORs = 1.56 and 2.13, 95% CIs = 1.02-2.38 and 1.22-3.70, respectively). These findings suggest that MMP1 promoter polymorphisms may individually or jointly play roles in the development of CM.

show abstract

Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case–control studies

Peng¹,

Cao²,

Wang³

et al. 2009

Mutagenesis

View full text Add to dashboard Cite

Matrix metalloproteinase (MMP) 1 and MMP3 are enzymes that degrade the extracellular matrix and have been implicated to play an important role in cancer development. Many studies have been carried out on the association between polymorphisms of MMP1 -1607 1G>2G and MMP3 -1171 5A>6A and cancer risk. However, results from these studies remain inconclusive. Here, we performed a meta-analysis of >38 000 subjects to better assess the purported associations. For MMP1, -1607 2G/2G genotype carriers were found to have an increased risk of colorectal cancer [2G/2G versus 2G/1G + 1G/1G, odds ratio (OR) = 1.48, 95% confidence interval (CI) (1.26-1.74), P(heterogeneity) = 0.066, I(2) = 49.3%], head and neck cancer [2G/2G versus 2G/1G + 1G/1G, OR = 1.61, 95% CI (1.26-2.07), P(heterogeneity) = 0.002, I(2) = 64.7%] and renal cancer [2G/2G versus 2G/1G + 1G/1G, OR = 1.82, 95% CI (1.38-2.39), P(heterogeneity) = 0.589, I(2) = 0.0%] risk. For MMP3, no association was found between -1171 5A>6A polymorphism and cancer risk in the overall group [6A versus 5A, OR = 1.00, 95% CI (0.95-1.05), P(heterogeneity) = 0.124, I(2) = 24.9%] and individual cancer subgroups, but stratified analysis by smoking status showed that this polymorphism had different effects on smokers and non-smokers under recessive genetic model. In summary, our study suggests that MMP1 -1607 2G may be associated with an increased cancer risk for certain types of cancers, MMP3 -1171 5A>6A may not be a major risk factor for cancer, but it may be modified by certain environmental factors. Future studies with larger sample sizes are warranted to further evaluate these associations in more detail.

show abstract

Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma

Cited by 4 publications

References 26 publications

MMP1, 2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis

MMP1, 2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis

Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma

Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case–control studies

Contact Info

Product

Resources

About